A Phase I, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Four-Period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Volunteers Aged 18 to 45 Years
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2010
At a glance
- Drugs Moxifloxacin; Zibotentan
- Indications Bacterial infections; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 05 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Aug 2008 New trial record.